贝伐珠单抗用于卵巢癌治疗的经济学研究综述

A Literature Review on Economic Evaluation of Bevacizumab in Treatment of Ovarian Cancer

关键词:  贝伐珠单抗  卵巢癌  经济学评价  成本效果

Key words:  bevacizumab  ovarian cancer  economic evaluation  cost-effectiveness

摘要:

目的 对贝伐珠单抗用于卵巢癌治疗的经济学研究进行综述，为贝伐珠单抗在卵巢癌治疗中的应用提供参考。方法 检索PubMed、Medline、Cochrane图书馆、中国期刊全文数据库（CNKI）、维普中文科技期刊全文数据库（VIP）、万方数据发表的贝伐珠单抗用于卵巢癌治疗的经济学评价文献并对其进行综述。结果 共纳入10项贝伐珠单抗用于卵巢癌治疗的药物经济学研究。对于卵巢癌一线化疗，多数研究结果表明贝伐珠单抗联合标准化疗方案相比单一化疗方案用于卵巢癌一线治疗的增量成本效果比超出了常用的意愿支付阈值。对于二线化疗，有研究显示贝伐珠单抗加入化疗方案具成本效果。结论 在常用的意愿支付阈值下，贝伐珠单抗加入到卵巢癌标准一线化疗方案相比单一化疗方案不具有成本效果。当贝伐珠单抗价格降低一定程度，贝伐珠单抗联合标准化疗的方案对于进展高风险的卵巢癌患者可成为具成本效果的选择。贝伐珠单抗用于铂耐药的卵巢癌治疗可具成本效果。

Abstract:

OBJECTIVE To review the economic evaluation of bevacizumab in treatment for patients with ovarian cancer. METHODS Search economic evaluation studies of bevacizumab for ovarian cancer on databases such as PubMed, Medline, Cochrane Library, CNKI, VIP Database and Wanfang Database. RESULTS Ten included studies demonstrate that incremental cost effectiveness ratio (ICER) of bevacizumab plus standard first-line chemotherapy versus chemotherapy alone exceeds the willingness-to-pay (WTP) threshold in most countries. Regarding platinum-resistant ovarian patients, adding bevacizumab to chemotherapy is cost-effective compared with chemotherapy alone. CONCLUSION Bevacizumab plus standard first-line chemotherapy is not cost-effective compared with chemotherapy alone in treatment of advanced ovarian. However, the combination of bevacizumab plus standard chemotherapy might be a cost-effective strategy given an enough reduction of drug price in ovarian patients at high risk of disease progression. As for second-line treatment, bevacizumab plus chemotherapy can be a cost-effective strategy.